Selective sodium-dependent glucose transporter 1 inhibitors block glucose absorption and impair glucose-dependent insulinotropic peptide release

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 308, Issue 11, 2015, Pages G946-G954

  Dobbins, Robert L ^a   Greenway, Frank L ^b   Chen, Lihong ^a   Liu, Yaping ^a   Breed, Sharon L ^a   Andrews, Susan M ^a   Wald, Jeffrey A ^a   Walker, Ann ^a   Smith, Chari D ^a  

^a GLAXOSMITHKLINE   (United States)

^b PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

Author keywords

Clinical trial; Gastric inhibitory peptide; GSK 1614235; KGA 2727

Indexed keywords

3 METHYLGLUCOSE; C PEPTIDE; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; GSK 1614235; INSULIN; KGA 2727; PEPTIDE YY; SODIUM GLUCOSE COTRANSPORTER 1; SODIUM GLUCOSE COTRANSPORTER INHIBITOR; TRACER; UNCLASSIFIED DRUG; 3-(3-(4-(3-(GLUCOPYRANOSYLOXY)-5-ISOPROPYL-1H-PYRAZOL-4-YLMETHYL)-3-METHYLPHENOXY)PROPYLAMINO)PROPIONAMIDE; GLUCOSIDE; PYRAZOLE DERIVATIVE;

ADULT; AGED; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEFECATION; DOWN REGULATION; DRUG EFFECT; DRUG SELECTIVITY; FEMALE; GLUCOSE ABSORPTION; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; HORMONE RELEASE; HUMAN; HUMAN EXPERIMENT; INSULIN BLOOD LEVEL; INTESTINE ABSORPTION; MALE; NONHUMAN; NORMAL HUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; TEST MEAL; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOAVAILABILITY; BLOOD; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECTS; DRUG MONITORING; INTESTINE MUCOSA; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; SMALL INTESTINE; TREATMENT OUTCOME;

3-O-METHYLGLUCOSE; ADMINISTRATION, ORAL; ADULT; ANIMALS; BIOLOGICAL AVAILABILITY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; FEMALE; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; GLUCOSIDES; HUMANS; INSULIN; INTESTINAL ABSORPTION; INTESTINAL MUCOSA; INTESTINE, SMALL; MALE; MIDDLE AGED; PYRAZOLES; RATS; SODIUM-GLUCOSE TRANSPORTER 1; TREATMENT OUTCOME;

EID: 84930902626     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.00286.2014     Document Type: Article

References (41)

1. Balen D, Ljubojevic M, Breljak D, Brzica H, Zlender V, Koepsell H, Sabolic I. Revised immunolocalization of the Na+-D-glucose cotransporter SGLT1 in rat organs with an improved antibody. Am J Physiol Cell Physiol 295: C475–C489, 2008.
2. Banerjee SK, McGaffin KR, Pastor-Soler NM, Ahmad F. SGLT1 is a novel cardiac glucose transporter that is perturbed in disease states. Cardiovasc Res 84: 111–118, 2009.
3. Ceriello A, Colagiuri S, Gerich J, Tuomilehto J. Guideline for management of postmeal glucose. Nutr Metab Cardiovasc Dis 18: S17–S33, 2008.
4. Chao EC, Henry RR. SGLT2 inhibition–a novel strategy for diabetes treatment. Nat Rev Drug Discov 9: 551–559, 2010.
5. Csaky TZ, GLENN JE. Urinary recovery of 3-methylglucose administered to rats. Am J Physiol 188: 159–162, 1957.
6. Csaky TZ, GLENN JE. Distribution of 3-methylglucose in organs of rat. Proc Soc Exp Biol Med 98: 400–401, 1958.
7. DECODE Study Group, the European Diabetes Epidemiology Group. Glucose tolerance, and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 161: 397–405, 2001.
8. Diedrich DF. In vitro evaluation of relative inhibitory potency of phlorizin and its congeners. Am J Physiol 209: 621–626, 1965.
9. Dyer J, Wood IS, Palejwala A, Ellis A, Shirazi-Beechey SP. Expression of monosaccharide transporters in intestine of diabetic humans. Am J Physiol Gastrointest Liver Physiol 282: G241–G248, 2002.
10. Ehrenkranz JR, Lewis NG, Kahn CR, Roth J. Phlorizin: a review. Diabetes Metab Res Rev 21: 31–38, 2005.
11. Elliott RM, Morgan LM, Tredger JA, Deacon S, Wright J, Marks V. Glucagon-like peptide-1 (7–36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns. J Endocrinol 138: 159–166, 1993.
12. Elsas LJ, Hillman RE, Patterson JH, Rosenberg LE. Renal and intestinal hexose transport in familial glucose-galactose malabsorption. J Clin Invest 49: 576–585, 1970.
13. Fordtran JS, Clodi PH, Soergel KH, Ingelfinger FJ. Sugar absorption tests, with special reference to 3-0-methyl-d-glucose and d-xylose. Ann Intern Med 57: 883–891, 1962.
14. Fukase N, Manaka H, Sugiyama K, Takahashi H, Igarashi M, Daimon M, Yamatani K, Tominaga M, Sasaki H. Response of truncated glucagon-like peptide-1 and gastric inhibitory polypeptide to glucose ingestion in non-insulin dependent diabetes mellitus. Effect of sulfonylurea therapy. Acta Diabetol 32: 165–169, 1995.
15. Fukase N, Takahashi H, Manaka H, Igarashi M, Yamatani K, Daimon M, Sugiyama K, Tominaga M, Sasaki H. Differences in glucagon-like peptide-1 and GIP responses following sucrose ingestion. Diabetes Res Clin Pract 15: 187–195, 1992.
16. Jang HJ, Kokrashvili Z, Theodorakis MJ, Carlson OD, Kim BJ, Zhou J, Kim HH, Xu X, Chan SL, Juhaszova M, Bernier M, Mosinger B, Margolskee RF, Egan JM. Gut-expressed gustducin and taste receptors regulate secretion of glucagon-like peptide-1. Proc Natl Acad Sci USA 104: 15069–15074, 2007.
17. Kuo P, Bellon M, Wishart J, Smout AJ, Holloway RH, Fraser RJ, Horowitz M, Jones KL, Rayner CK. Effects of metoclopramide on duodenal motility and flow events, glucose absorption, and incretin hormone release in response to intraduodenal glucose infusion. Am J Physiol Gastrointest Liver Physiol 299: G1326–G1333, 2010.
18. Kuo P, Wishart JM, Bellon M, Smout AJ, Holloway RH, Fraser RJ, Horowitz M, Jones KL, Rayner CK. Effects of physiological hyperglycemia on duodenal motility and flow events, glucose absorption, and incretin secretion in healthy humans. J Clin Endocrinol Metab 95: 3893–3900, 2010.
19. Margolskee RF, Dyer J, Kokrashvili Z, Salmon KS, Ilegems E, Daly K, Maillet EL, Ninomiya Y, Mosinger B, Shirazi-Beechey SP. T1R3 and gustducin in gut sense sugars to regulate expression of Na+-glucose cotransporter 1. Proc Natl Acad Sci USA 104: 15075–15080, 2007.
20. Masumoto S, Akimoto Y, Oike H, Kobori M. Dietary phloridzin reduces blood glucose levels and reverses Sglt1 expression in the small intestine in streptozotocin-induced diabetic mice. J Agric Food Chem 57: 4651–4656, 2009.
21. Merigo F, Benati D, Cristofoletti M, Osculati F, Sbarbati A. Glucose transporters are expressed in taste receptor cells. J Anat 219: 243–252, 2011.
22. Moriya R, Shirakura T, Ito J, Mashiko S, Seo T. Activation of sodium-glucose cotransporter 1 ameliorates hyperglycemia by mediating incretin secretion in mice. Am J Physiol Endocrinol Metab 297: E1358–E1365, 2009.
23. O’Keefe JH, Bell DS. Postprandial hyperglycemia/hyperlipidemia (postprandial dysmetabolism) is a cardiovascular risk factor. Am J Cardiol 100: 899–904, 2007.
24. O’Malley D, Reimann F, Simpson AK, Gribble FM. Sodium-coupled glucose cotransporters contribute to hypothalamic glucose sensing. Diabetes 55: 3381–3386, 2006.
25. Parker HE, Habib AM, Rogers GJ, Gribble FM, Reimann F. Nutrientdependent secretion of glucose-dependent insulinotropic polypeptide from primary murine K cells. Diabetologia 52: 289–298, 2009.
26. Qiao Q, Tuomilehto J, Borch-Johnsen K. Post-challenge hyperglycaemia is associated with premature death and macrovascular complications. Diabetologia 46, Suppl 1: M17–M21, 2003.
27. Reimann F, Habib AM, Tolhurst G, Parker HE, Rogers GJ, Gribble FM. Glucose sensing in L cells: a primary cell study. Cell Metab 8: 532–539, 2008.
28. Sabolic I, Skarica M, Gorboulev V, Ljubojevic M, Balen D, Herak-Kramberger CM, Koepsell H. Rat renal glucose transporter SGLT1 exhibits zonal distribution and androgen-dependent gender differences. Am J Physiol Renal Physiol 290: F913–F926, 2006.
29. Shibazaki T, Tomae M, Ishikawa-Takemura Y, Fushimi N, Itoh F, Yamada M, Isaji M. KGA-2727, a novel selective inhibitor of highaffinity sodium glucose cotransporter (SGLT1), exhibits antidiabetic efficacy in rodent models. J Pharmacol Exp Ther 342: 288–296, 2012.
30. Shirazi-Beechey SP, Moran AW, Batchelor DJ, Daly K, Al-Rammahi M. Glucose sensing and signalling; regulation of intestinal glucose transport. Proc Nutr Soc 70: 185–193, 2011.
31. Stearns AT, Balakrishnan A, Rhoads DB, Tavakkolizadeh A. Rapid upregulation of sodium-glucose transporter SGLT1 in response to intestinal sweet taste stimulation. Ann Surg 251: 865–871, 2010.
32. Suzuki T, Fujikura K, Koyama H, Matsuzaki T, Takahashi Y, Takata K. The apical localization of SGLT1 glucose transporter is determined by the short amino acid sequence in its N-terminal domain. Eur J Cell Biol 80: 765–774, 2001.
33. Turk E, Zabel B, Mundlos S, Dyer J, Wright EM. Glucose/galactose malabsorption caused by a defect in the Na+/glucose cotransporter. Nature 350: 354–356, 1991.
34. Uhing MR, Kimura RE. Active transport of 3-O-methyl-glucose by the small intestine in chronically catheterized rats. J Clin Invest 95: 2799–2805, 1995.
35. Wright EM, Hirayama BA, Loo DF. Active sugar transport in health and disease. J Intern Med 261: 32–43, 2007.
36. Wright EM, Loo DD, Hirayama BA. Biology of human sodium glucose transporters. Physiol Rev 91: 733–794, 2011.
37. Wright EM, Turk E. The sodium/glucose cotransport family SLC5. Pflugers Arch 447: 510–518, 2004.
38. Wright EM, Turk E, Martin MG. Molecular basis for glucose-galactose malabsorption. Cell Biochem Biophys 36: 115–121, 2002.
39. Wu T, Zhao BR, Bound MJ, Checklin HL, Bellon M, Little TJ, Young RL, Jones KL, Horowitz M, Rayner CK. Effects of different sweet preloads on incretin hormone secretion, gastric emptying, and postprandial glycemia in healthy humans. Am J Clin Nutr 95: 78–83, 2012.
40. Zambrowicz B, Ding ZM, Ogbaa I, Frazier K, Banks P, Turnage A, Freiman J, Smith M, Ruff D, Sands A, Powell D. Effects of LX4211, a dual SGLT1/SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control in type 2 diabetes. Clin Ther 35: 273–285, 2013.
41. Zambrowicz B, Ogbaa I, Frazier K, Banks P, Turnage A, Freiman J, Boehm KA, Ruff D, Powell D, Sands A. Effects of LX4211, a dual sodium-dependent glucose cotransporters 1 and 2 inhibitor, on postprandial glucose, insulin, glucagon-like peptide 1, and peptide tyrosine tyrosine in a dose-timing study in healthy subjects. Clin Ther 35: 1162–1173, 2013.